Keyword: Ziopharm Oncology
A phase 1 clinical trial of Ziopharm's IL-12 gene therapy and a production "switch" shows promise in recurrent glioblastoma.
Merck beefs up digital work with consumer executive; F-star names ex-Immunocore CEO as leader; and Ziopharm’s R&D head joins Spectrum as CMO.
Ziopharm Oncology’s executive vice president of R&D, Francois Lebel, M.D., is moving to cancer drugmaker Spectrum Pharmaceuticals effective Nov. 5.
Ziopharm wants to run the study to assess CAR-T cells manufactured at the point of care, but the FDA is demanding more CMC information.
Management took the action after technical issues slowed progress of the inducible adenoviral vector.